Fig. 1

Multiperiod of 2ccPA administration protocol. For protocol A, 2ccPA was administered once daily via intraperitoneal injection for the duration of the 5-week period of cuprizone exposure (0–5 weeks: acute peak demyelination). For protocol B, 2ccPA was administered once daily via intraperitoneal injection between weeks 3–5 of cuprizone exposure (3–5 weeks: after onset of demyelination). For protocol C, 2ccPA was administered once daily via intraperitoneal injection between weeks 5–6 of cuprizone exposure (5–6 weeks: spontaneous remyelination). For protocol D, 2ccPA was administered once daily via intraperitoneal injection between weeks 5–10 of cuprizone exposure (5–10 weeks: chronic demyelination)